Cargando…

Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada

For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whethe...

Descripción completa

Detalles Bibliográficos
Autores principales: Ball, Graeme, Lemieux, Christopher, Cameron, David, Seftel, Matthew D.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/
https://www.ncbi.nlm.nih.gov/pubmed/35323364
http://dx.doi.org/10.3390/curroncol29030164
_version_ 1784674331156021248
author Ball, Graeme
Lemieux, Christopher
Cameron, David
Seftel, Matthew D.
author_facet Ball, Graeme
Lemieux, Christopher
Cameron, David
Seftel, Matthew D.
author_sort Ball, Graeme
collection PubMed
description For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data.
format Online
Article
Text
id pubmed-8946986
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-89469862022-03-25 Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada Ball, Graeme Lemieux, Christopher Cameron, David Seftel, Matthew D. Curr Oncol Article For patients with Mantle Cell Lymphoma (MCL), there is no recognized standard of care for relapsed/refractory (R/R) disease after treatment with a Bruton’s tyrosine kinase inhibitor (BTKi). Brexucabtagene autoleucel (brexu-cel) represents a promising new treatment modality in MCL. We explored whether brexu-cel was cost-effective for the treatment of R/R MCL. We developed a partitioned survival mixture cure approach to model the costs and outcomes over a lifetime horizon. The clinical data were derived from the ZUMA-2 clinical trial. The costs were estimated from the publicly available Canadian databases, published oncology literature, and pan-Canadian Oncology Drug Review economic guidance reports. The health state utilities were sourced from the ibrutinib submission to the National Institute for Health and Care Excellence for R/R MCL and supplemented with values from the published oncology literature. In the base case over a lifetime horizon, brexu-cel generated an incremental 9.56 life-years and an additional 7.03 quality-adjusted life-years compared to BSC, while associated with CAD 621,933 in additional costs. The resultant incremental cost-utility ratio was CAD 88,503 per QALY gained compared with BSC. Based on this analysis, we found brexu-cel to be a cost-effective use of healthcare resources relative to BSC for treatment of adult patients with R/R MCL previously treated with a BTKi in Canada, though additional research is needed to confirm these results using longer follow-up data. MDPI 2022-03-17 /pmc/articles/PMC8946986/ /pubmed/35323364 http://dx.doi.org/10.3390/curroncol29030164 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ball, Graeme
Lemieux, Christopher
Cameron, David
Seftel, Matthew D.
Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title_full Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title_fullStr Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title_full_unstemmed Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title_short Cost-Effectiveness of Brexucabtagene Autoleucel versus Best Supportive Care for the Treatment of Relapsed/Refractory Mantle Cell Lymphoma following Treatment with a Bruton’s Tyrosine Kinase Inhibitor in Canada
title_sort cost-effectiveness of brexucabtagene autoleucel versus best supportive care for the treatment of relapsed/refractory mantle cell lymphoma following treatment with a bruton’s tyrosine kinase inhibitor in canada
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8946986/
https://www.ncbi.nlm.nih.gov/pubmed/35323364
http://dx.doi.org/10.3390/curroncol29030164
work_keys_str_mv AT ballgraeme costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada
AT lemieuxchristopher costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada
AT camerondavid costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada
AT seftelmatthewd costeffectivenessofbrexucabtageneautoleucelversusbestsupportivecareforthetreatmentofrelapsedrefractorymantlecelllymphomafollowingtreatmentwithabrutonstyrosinekinaseinhibitorincanada